Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Spero Therapeutics (NASDAQ: SPRO ) stock is climbing higher on Wednesday thanks to positive feedback from the FDA. That concerns plans to resubmit tebipenem HBr for the treatment of comp...
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resista...
3 Penny Stocks to Add to Your Watchlist Right Now With so many penny stocks to choose from, it can be difficult to understand which ones are worth buying. Right now, there is a lot going on in the stock market with both penny stocks and blue chips . And because of this, knowing ...
Spero Therapeutics, Inc. ( NASDAQ: SPRO ) surged ~64% Tuesday after the clinical-stage biotech announced that the FDA agreed to review results from a single additional Phase 3 trial to support a potential marketing approval for its investigational UTI antibiotic tebipenem ...
Alignment with the FDA on a regulatory path forward for the continued development of tebipenem Hbr FDA feedback indicates positive results from a single additional Phase 3 clinical trial in patients with complicated urinary tract infection (cUTI), with supportive confirmatory ev...
Spero Therapeutics, Inc. (SPRO) Q2 2022 Earnings Conference Call August 10, 2022 04:30 PM ET Company Participants Ted Jenkins - Vice President-Investor Relations & Strategic Finance Ankit Mahadevia - Chief Executive Officer David Melnick - Consultant & Se...
Spero Therapeutics press release ( NASDAQ: SPRO ): Q2 GAAP EPS of -$0.87. Revenue of $1.99M (-61.4% Y/Y). As of June 30, 2022, Spero had cash, cash equivalents, and marketable securities of $45.4 million. Shares +5% . For further details see: Spero Th...
Initiation of a Placebo-controlled Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Expected in 4Q 2022 Initiation of a Phase 2 Cross-indication Resistant Pathogen Trial of SPR206 Expected in 3Q 2023 Continued Engagement with FDA is Expe...
CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022 at 4:30 p.m. ET to report its second quarter 2022 financial results and provide an update...
New York, New York--(Newsfile Corp. - July 25, 2022) - Levi & Korsinsky, LLP notifies investors in Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) of a class action securities lawsuit. The lawsuit on behalf of Spero investors has been commenced in the the United State...
News, Short Squeeze, Breakout and More Instantly...
Spero Therapeutics Inc. Company Name:
SPRO Stock Symbol:
NASDAQ Market:
Spero Therapeutics Inc. Website:
CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced t...
CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced tha...
On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024 Enrollment ongoing in PIVOT-PO, a pivotal Phase 3 clinical trial of oral tebipenem HBr in cUTI Received FDA Fast...